Advanced MRI Assessment during Dendritic Cell Immunotherapy Added to Standard Treatment Against Glioblastoma.
DSC-MRI
DWI-MRI
Glioblastoma
Immunotherapy
Pseudoprogression
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
17 Nov 2019
17 Nov 2019
Historique:
received:
18
09
2019
revised:
12
11
2019
accepted:
13
11
2019
entrez:
21
11
2019
pubmed:
21
11
2019
medline:
21
11
2019
Statut:
epublish
Résumé
Evaluating changes induced by immunotherapies (IT) on conventional magnetic resonance imaging (MRI) is difficult because those treatments may produce inflammatory responses. To explore the potential contribution of advanced MRI to distinguish pseudoprogression (PsP) and true tumor progression (TTP), and to identify patients obtaining therapeutic benefit from IT, we examined aMRI findings in newly diagnosed glioblastoma treated with dendritic cell IT added to standard treatment. We analyzed longitudinal MRIs obtained in 22 patients enrolled in the EUDRACT N° 2008-005035-15 trial. According to RANO criteria, we observed 18 TTP and 8 PsP. Comparing MRI performed at the time of TTP/PsP with the previous exam performed two months before, a difference in cerebral blood volume ΔrCBV
Identifiants
pubmed: 31744235
pii: jcm8112007
doi: 10.3390/jcm8112007
pmc: PMC6912338
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Neuroradiology. 2017 Feb;59(2):135-145
pubmed: 28070598
J Clin Oncol. 2010 May 1;28(13):2293-9
pubmed: 20368564
Neuro Oncol. 2017 Jan;19(1):89-98
pubmed: 27580889
Am Soc Clin Oncol Educ Book. 2016;35:e132-9
pubmed: 27249715
Radiology. 2009 Mar;250(3):887-96
pubmed: 19244052
Neuroradiology. 2011 Oct;53(10):721-31
pubmed: 21107549
NMR Biomed. 2014 Sep;27(9):1046-52
pubmed: 25042540
Immunity. 2007 Apr;26(4):503-17
pubmed: 17398124
Lancet Oncol. 2017 Oct;18(10):1373-1385
pubmed: 28844499
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
PLoS One. 2012;7(12):e52301
pubmed: 23284979
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
J Neurooncol. 2017 Sep;134(3):495-504
pubmed: 28382534
Lancet Oncol. 2008 May;9(5):453-61
pubmed: 18452856
Oncoimmunology. 2014 Jun 25;3:e29381
pubmed: 25083342
Lancet Oncol. 2015 Nov;16(15):e534-e542
pubmed: 26545842
Neuro Oncol. 2017 Mar 1;19(3):454-456
pubmed: 28039369
AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1455-60
pubmed: 15956515
Cancer Immunol Immunother. 1997 Oct;45(2):77-87
pubmed: 9390198
J Immunol Res. 2014;2014:796856
pubmed: 24804271
Expert Opin Biol Ther. 2016 Nov;16(11):1373-1385
pubmed: 27564141
Radiology. 2010 Aug;256(2):575-84
pubmed: 20529987
Front Neurol. 2015 Feb 23;6:33
pubmed: 25755649
Neuro Oncol. 2017 Jan;19(1):118-127
pubmed: 27502247
AJNR Am J Neuroradiol. 2000 May;21(5):901-9
pubmed: 10815666
Am J Clin Oncol. 2017 Jun;40(3):228-234
pubmed: 25436828
Acad Radiol. 2012 Nov;19(11):1353-61
pubmed: 22884399
AJR Am J Roentgenol. 1988 Jan;150(1):189-97
pubmed: 3257119
Clin Cancer Res. 2018 Jan 1;24(1):52-61
pubmed: 29018053
Radiology. 2009 Nov;253(2):486-96
pubmed: 19789240
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
J Magn Reson Imaging. 2010 Mar;31(3):538-48
pubmed: 20187195
AJNR Am J Neuroradiol. 2004 Feb;25(2):201-9
pubmed: 14970018
Neurotherapeutics. 2017 Apr;14(2):307-320
pubmed: 28108885
Oncoimmunology. 2018 Jan 29;7(4):e1412901
pubmed: 29632727